Protection of Tregs, Suppression of Th1 and Th17 Cells, and Amelioration of Experimental Allergic Encephalomyelitis by a Physically-Modified Saline

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Mondal, Susanta ^a   Martinson, Jeffrey A ^a   Ghosh, Supurna ^b   Watson, Richard ^b   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Revalesio Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; NITRIC OXIDE; NITRIC OXIDE DONOR; SODIUM CHLORIDE; SODIUM CHLORIDE RNS60; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME REGULATION; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; OXYGEN TENSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TARGET CELL; TH1 CELL; TH17 CELL; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; BLOTTING, WESTERN; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MICE; NITRIC OXIDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM CHLORIDE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

ANIMALIA;

EID: 84871407858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051869     Document Type: Article

References (41)

1. Coffer PJ, Burgering BM, (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4: 889-899.
2. Hori S, Nomura T, Sakaguchi S, (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
3. Sakaguchi S, Powrie F, (2007) Emerging challenges in regulatory T cell function and biology. Science 317: 627-629.
4. Sakaguchi S, (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352.
5. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, et al. (2005) Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81: 45-52.
6. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA, (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979.
7. Paust S, Cantor H, (2005) Regulatory T cells and autoimmune disease. Immunol Rev 204: 195-207.
8. McGeachy MJ, Stephens LA, Anderton SM, (2005) Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175: 3025-3032.
9. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al. (2008) Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89.
10. Pahan K, (2010) Neuroimmune pharmacological control of EAE. J Neuroimmune Pharmacol 5: 165-167.
11. Pahan K, (2011) Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate. Immunopharmacol Immunotoxicol 33: 586-593.
12. Khasnavis S, Jana A, Roy A, Mazumder M, Bhushan B, et al. (2012) Suppression of Nuclear Factor-kappaB Activation and Inflammation in Microglia by Physically Modified Saline. J Biol Chem 287: 29529-29542.
13. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, et al. (2004) Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 173: 1344-1354.
14. Dasgupta S, Zhou Y, Jana M, Banik NL, Pahan K, (2003) Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol 170: 3874-3882.
15. Brahmachari S, Pahan K, (2007) Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. J Immunol 179: 275-283.
16. Mondal S, Roy A, Pahan K, (2009) Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 182: 5013-5023.
17. Brahmachari S, Pahan K, (2010) Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J Immunol 184: 1799-1809.
18. Brahmachari S, Pahan K, (2009) Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J Immunol 183: 2045-2058.
19. Pahan K, Sheikh FG, Namboodiri AM, Singh I, (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100: 2671-2679.
20. Dasgupta S, Jana M, Liu X, Pahan K, (2003) Role of very-late antigen-4 (VLA-4) in myelin basic protein-primed T cell contact-induced expression of proinflammatory cytokines in microglial cells. J Biol Chem 278: 22424-22431.
21. Kohm AP, Carpentier PA, Anger HA, Miller SD, (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 169: 4712-4716.
22. McKee AS, Pearce EJ, (2004) CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol 173: 1224-1231.
23. El-behi M, Rostami A, Ciric B, (2010) Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 5: 189-197.
24. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, et al. (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326: 986-991.
25. Shi G, Cox CA, Vistica BP, Tan C, Wawrousek EF, et al. (2008) Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol 181: 7205-7213.
26. Schrempf W, Ziemssen T, (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6: 469-475.
27. Zhu J, Paul WE, (2010) CD4+ T cell plasticity-Th2 cells join the crowd. Immunity 32: 11-13.
28. Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K, (2007) Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 72: 934-946.
29. Kuerten S, Lehmann PV, (2011) The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis? J Interferon Cytokine Res 31: 907-916.
30. Martin R, McFarland HF, McFarlin DE, (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153-187.
31. Chun J, Hartung HP, (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
32. Sabatino JJ Jr, Rosenthal KM, Evavold BD, (2010) Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. J Neuroimmune Pharmacol 5: 176-188.
33. Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, et al. (2010) Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol 5: 231-239.
34. Ziegler SF, (2006) FOXP3: of mice and men. Annu Rev Immunol 24: 209-226.
35. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, et al. (2010) Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 7: 3.
36. Rapoport N, Gao Z, Kennedy A, (2007) Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99: 1095.
37. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, et al. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029.
38. Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, et al. (2003) CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol 170: 394-399.
39. Reddy J, Waldner H, Zhang X, Illes Z, Wucherpfennig KW, et al. (2005) Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol 175: 5591-5595.
40. Miller A, (1997) Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med J 90: 367-375.
41. Cohen JA, Reingold SC, Polman CH, Wolinsky JS, (2012) Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 11: 467-476.